GlassScriptPhysician profile
Glenn L Osias
NPI 1164422788
$12,253.94
in general payments reported to CMS, 2019-2025
44 companies · $2,510 in 2025
The $2,510 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,410 · 2020: $489 · 2021: $721 · 2022: $1,848 · 2023: $2,431 · 2024: $2,844 · 2025: $2,510.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,490 · Education: $255 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.00 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,490.06 |
| Education | $255.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.00 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,192.53 | 2019-2025 | |
| Janssen Biotech, INC. | $1,453.73 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,130.07 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $893.04 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $593.14 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $490.89 | 2019-2024 | Linzess |
| Braintree Laboratories, INC. | $412.16 | 2019-2025 | Sutab, Suflave |
| Phathom Pharmaceuticals, INC. | $365.83 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $333.60 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $328.04 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $309.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $309.02 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $210.94 | 2019-2024 | Ocaliva |
| Lilly USA, LLC | $209.40 | 2023-2025 | Omvoh |
| Ferring Pharmaceuticals INC. | $159.08 | 2019-2024 | Rebyota |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $145.72 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $143.86 | 2022-2025 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $141.95 | 2024-2025 | Iqirvo, Bylvay |
| Boston Scientific Corporation | $140.89 | 2023-2024 | Exalt Model D, Cre Pro |
| Aimmune Therapeutics, INC. | $136.62 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $125.19 | 2021-2023 | |
| Ucb, INC. | $124.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $120.98 | 2019-2023 | Dificid |
| Gilead Sciences, INC. | $120.11 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $119.70 | 2020 | |
| Genzyme Corporation | $74.89 | 2022-2025 | |
| Organon LLC | $59.95 | 2023 | Renflexis, Hadlima |
| Celltrion USA INC. | $35.57 | 2025 | Vegzelma |
| Sandoz INC. | $35.27 | 2023-2024 | Hyrimoz |
| Fresenius Kabi USA, LLC | $34.62 | 2023 | Idacio |
| Exact Sciences Corporation | $31.68 | 2023-2025 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $29.84 | 2020-2022 | |
| Medtronic, INC. | $28.50 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $27.32 | 2022 | |
| Redhill Biopharma INC. | $25.93 | 2020-2021 | |
| Amgen INC. | $25.03 | 2023 | Amjevita |
| Ethicon US, LLC | $21.62 | 2019 | |
| Orphalan INC | $17.98 | 2024 | Cuvrior |
| Albireo Pharma, INC. | $17.10 | 2023 | Bylvay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.67 | 2024 | Cyltezo |
| Romark Laboratories, Lc | $16.20 | 2020 | |
| Novo Nordisk INC | $16.02 | 2025 | Wegovy |
| Mauna Kea Technologies, INC. | $15.44 | 2019 | |
| W. L. Gore & Associates, INC. | $14.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Osias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.